EuroscreenFast

Executive Summary

EuroscreenFast is a privately held Belgian company with over 25 years of specialized expertise in GPCR (G protein-coupled receptor) screening assays, cell lines, and custom development services. Based in Brussels, the company supports all stages of preclinical GPCR drug discovery, from target identification and high-throughput screening (HTS) to profiling and lead optimization. Their offerings include off-the-shelf assays and cell lines, as well as tailored solutions for clients in the pharmaceutical and biotechnology sectors. With a strong track record and a dedicated team of scientists, EuroscreenFast serves as a key partner for organizations seeking reliable, high-quality GPCR tools to accelerate their drug development pipelines. The company’s deep domain knowledge and established infrastructure position it well to capitalize on the growing demand for GPCR-targeted therapeutics, which account for a significant portion of approved drugs. As the GPCR drug discovery market continues to expand, EuroscreenFast is poised to benefit from increased outsourcing of assay development and screening services by biopharma companies.

Upcoming Catalysts (preview)

• Q2 2026Launch of a next-generation GPCR assay platform (e.g., BRET or NanoBiT-based)70% success
• Q4 2026Strategic partnership with a top-20 pharmaceutical company for GPCR screening services50% success
• TBDExpansion into orphan GPCR targets for rare diseases40% success